As­traZeneca on emerg­ing mar­kets, GLP-1 plans and why it’s se­lec­tive about vac­cines

As­traZeneca put the spot­light on its near-20% rev­enue growth dur­ing first-quar­ter earn­ings, dri­ven in part by its suc­cess in emerg­ing mar­kets.

Ex­ec­u­tives on the com­pa­ny’s an­a­lyst call dis­cussed de­vel­op­ment plans for its ear­ly-stage obe­si­ty drug, its se­lec­tive ap­proach to vac­cine in­vest­ments and de­fend­ed the com­pa­ny against crit­i­cisms that it was spread­ing it­self too thin across var­i­ous drug modal­i­ties. Here are six key take­aways:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER